Abstracts Archive - Page 833 of 2425 - ACR Meeting Abstracts

Abstract Number: 1119 • 2019 ACR/ARP Annual Meeting
Patterns of Medication Use for Patients with Sarcoidosis: Data from the ACR’s RISE Registry
Gabriela Schmajuk¹, Julia Kay ², Jing Li ², Sonam Choden ¹, Esi Morgan ³, Jinoos Yazdany ² and Andreas Reimold ⁴, ¹UCSF, SFVAMC Division of Rheumatology, San Francisco, CA, ²UCSF Division of Rheumatology, San Francisco, CA, ³Cincinnati Children’s Hospital, University of Cincinnati, Cinncinati, OH, ⁴Dallas VA and Univ of Texas Southwestern Medical Centers, Dallas, TX
Background/Purpose: Sarcoidosis results in significant morbidity and mortality but is a generally understudied disease. There are currently no FDA approved drugs for the treatment of…
Abstract Number: 1120 • 2019 ACR/ARP Annual Meeting
Prevalence of Burnout in Rheumatology Professionals
Vivekanand Tiwari¹, Arthur Kavanaugh ², George Martin ³ and Martin Bergman ⁴, ¹Temple University, Philadelphia, PA, ²University of California, San Diego School of Medicine, La Jolla, CA, ³Dr. George Martin Dermatology Associates, Kihei, HI, ⁴Drexel University College of Medicine, Stockholm, Sweden
Background/Purpose: Burnout among physicians has major implications for health care. We measured prevalence of burnout in a large group of Rheumatology professionals attending a national…
Abstract Number: 1121 • 2019 ACR/ARP Annual Meeting
The Association Between Physician Sex and Faculty Rank Among Academic Rheumatologists in the United States
April Jorge¹, Xiaoqing Fu ², Daniel Blumenthal ², Nate Gross ³, Marcy Bolster ¹ and Zachary Wallace ², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Doximity, San Francisco, CA
Background/Purpose: In contrast to historical trends, women now comprise more than half of rheumatology fellowship graduates in the United States (US). Differences in academic rank…
Abstract Number: 1122 • 2019 ACR/ARP Annual Meeting
Factors Impacting Referral of Juvenile Idiopathic Arthritis Patients to a Tertiary Level Pediatric Rheumatology Center in North India
Caroline Freychet ¹, Manjari Agarwal ², Sumidha Mittal ², Abhay Shivpuri ², Anju Singh ², Veronique Dinand ³ and Sujata Sawhney², ¹Department of pediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India, New Delhi, Delhi, India, ²Department of pediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India, New Delhi, India, ³Department of research, Sir Ganga Ram Hospital, New Delhi, India, New Dehli, India
Background/Purpose: JIA studies demonstrate that there is a “window of opportunity” early in the disease course during which appropriate management improves outcomes: prompt referral to…
Abstract Number: 1123 • 2019 ACR/ARP Annual Meeting
Healthcare Factors More Predictive of Smoking Cessation in Patients with Rheumatoid Arthritis Than Patient Characteristics
Maria Schletzbaum¹, Xing Wang ¹, Robert Greenlee ² and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Marshfield Clinic Research Institute, Marshfield, WI
Background/Purpose: Smoking doubles the risk of developing RA, and continuing to smoke after RA diagnosis is associated with worse disease control, treatment failure, and premature…
Abstract Number: 1124 • 2019 ACR/ARP Annual Meeting
The Direct and Indirect Costs of Illness Associated with Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review
Jennifer Lofland¹, Pamela Berry ², Feng Pan ², Chetan Karyekar ³, Hannah Guiang ⁴, Rebecca McTavish ⁴ and Melissa Thompson ⁴, ¹Janssen Scientific Affairs, LLC, Spring House, PA, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Global Services, LLC, Horsham, PA, ⁴Cornerstone Research Group, Inc, Burlington, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. SLE tends to peak during prime working years, resulting in a high economic burden due…
Abstract Number: 1125 • 2019 ACR/ARP Annual Meeting
Health Care Resource Utilization and Costs in Patients with Juvenile Idiopathic Arthritis Treated with Abatacept and Other Targeted Disease Modifying Anti-rheumatic Drugs
Joe Zhuo¹, Ying Bao ², Qian Xia ², Aarti Rao ³, Niyati Sharma ³, Xue Han ⁴ and Robert Wong ⁵, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Lawrenceville, NJ, ³Mu Sigma, Bangalore, India, ⁴Bristol-Myers Squibb Company, Princeton, NJ, ⁵Bristol-Myers Squibb, Princeton
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a common, chronic rheumatic disease of childhood that carries substantial economic impact on patients (pts) and families1. The objective…
Abstract Number: 1126 • 2019 ACR/ARP Annual Meeting
A Medical Assistant Driven Quality Improvement Intervention Increases Rates of DEXA Screening Among RA Patients
Sarah French¹, Joshua Ng ¹, Darlene Young ², Michael Evans ³, Tobias Schmelzinger ¹, Gabriela Schmajuk ⁴, Jinoos Yazdany ⁵ and Andrew Gross ¹, ¹UCSF, San Francisco, CA, ²UCSF, San Francisco, ³University of California San Francisco, San Francisco, ⁴UCSF, SFVAMC Division of Rheumatology, San Francisco, CA, ⁵UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk for developing osteoporosis as compared to the general population, even after controlling for glucocorticoid use[1]. Identification…
Abstract Number: 1127 • 2019 ACR/ARP Annual Meeting
Interventions to Improve Time to Appointment and Outcome Variables in the Pediatric to Adult Transition of Care in Rheumatology
Nicole Bitencourt¹, Una Makris ², Bonnie Bermas ³, Tracey Wright ⁴ and Elizabeth Solow ⁵, ¹UT Southwestern Medical Center, Dallas, ²UT Southwestern Medical Center and Dallas VA Medical Center, Dallas, ³UT Southwestern, Dallas, ⁴University of Texas Southwestern, Texas Scottish Rite Hospital for Children, Children's Health, Dallas, TX, ⁵UT Southwestern Medical Center, Dallas, TX
Background/Purpose: The transition from pediatric to adult care is a vulnerable period, in which poor health outcomes are reported amongst youth transferring to adult care.…
Abstract Number: 1128 • 2019 ACR/ARP Annual Meeting
Physician-Patient Interaction and Medication Adherence in Lupus Nephritis
Sofia Georgopoulou¹, Louise Nel ², Shirish Sangle ² and David D'Cruz ³, ¹King's College London & The Royal Marsden Hospital NHS Foundation Trust, London, England, United Kingdom, ²Guy's & St Thomas' Hospitals NHS Foundation Trust, London, England, United Kingdom, ³The Louise Coote Lupus Unit, Guy's Hospital, London, England, United Kingdom
Background/Purpose: The quality of physician-patient interaction can have a significant impact on medication adherence. Little is known about this relationship in patients with lupus nephritis…
Abstract Number: 1129 • 2019 ACR/ARP Annual Meeting
Direct Medical and Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States
Jamie Huizinga¹, Elizabeth Stanley ¹, Shuang Song ¹, James Sullivan ², Jeffrey Katz ³ and Elena Losina ⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital/Harvard Medical School, Boston, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Symptomatic knee OA affects 14 million adults in the US. Recent estimates suggest that about 40% of people with knee OA are taking prescription…
Abstract Number: 1130 • 2019 ACR/ARP Annual Meeting
The Risk of Toxic Retinopathy Among Patients on Hydroxychloroquine
Abdulrahman Alrashid¹, Millicent Anne Stone ², Nigel Davies ² and David D'Cruz ³, ¹King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia, ²Guy's and St Thomas Foundation Trust, London, United Kingdom, ³The Louise Coote Lupus Unit, Guy's Hospital, London, England, United Kingdom
Background/Purpose: Background: Hydroxychloroquine (HCQ) is widely used in treatment of autoimmune rhuematological diseases. In particular, systemic lupus erythermatosus where it proved to prevent disease flare, reduce…
Abstract Number: 1131 • 2019 ACR/ARP Annual Meeting
Loss to Follow-up in Registries of Rheumatic Patients Treated with Biologics: A Potentially Valuable Hidden Real-world Data That Is Being Overlooked?
Ana Valido¹, Joana Silva-Dinis ², Rita Cruz-Machado ³, Maria João Gonçalves ⁴, Vasco Romao ⁵, Maria João Saavedra ¹ and João Eurico Fonseca ², ¹Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN; Lisboa, Portugal., Lisbon, Portugal, ²Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa; Centro Académico de Medicina de Lisboa; Lisbon, Portugal., Lisbon, Portugal, ³Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHULN; Lisboa, Portugal. Centro Académico de Medicina de Lisboa, Portugal., Lisbon, Portugal, ⁴Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon., Lisbon, Portugal, ⁵University of Lisbon, Lisbon, Portugal
Background/Purpose: The information associated with loss to follow-up (LFU) patients may affect real-world data evaluation of the use of biologics that is not being adequately…
Abstract Number: 1132 • 2019 ACR/ARP Annual Meeting
Facility-Level Variation in Biologic Disease Modifying Agents for Medicare Enrollees with Rheumatoid Arthritis
Deepan Dalal¹, Tingting Zhang ², Hiren Verma ³ and Theresa Shireman ², ¹Brown University, Riverside, RI, ²Brown University, Providence, RI, ³Brown University School of Public Health, Providence, RI
Background/Purpose: Biologic disease modifying agents (DMARDs) are an integral part of rheumatoid arthritis (RA) treatment, but the adoption of infusion-based products has not been reported.…
Abstract Number: 1133 • 2019 ACR/ARP Annual Meeting
Medicare Spending (2012-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis
Deepan Dalal¹, Tingting Zhang ² and Theresa Shireman ², ¹Brown University, Riverside, RI, ²Brown University, Providence, RI
Background/Purpose: Biologic disease modifying agents (DMARDs) have become an integral part of rheumatoid arthritis (RA) treatment guidelines, but they are associated with a substantial increase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].